1. Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy.
- Author
-
Qiang, Li, Hoffman, Megan T., Ali, Lestat R., Castillo, Jaime I., Kageler, Lauren, Temesgen, Ayantu, Lenehan, Patrick, Wang, S. Jennifer, Bello, Elisa, Cardot-Ruffino, Victoire, Uribe, Giselle A., Yang, Annan, Dougan, Michael, Aguirre, Andrew J., Raghavan, Srivatsan, Pelletier, Marc, Cremasco, Viviana, and Dougan, Stephanie K.
- Abstract
Transforming growth factor-b (TGFb) plays pleiotropic roles in pancreatic cancer, including promoting metastasis, attenuating CD8 T-cell activation, and enhancing myofibroblast differentiation and deposition of extracellular matrix. However, single-agent TGFb inhibition has shown limited efficacy against pancreatic cancer in mice or humans. We evaluated the TGFβ-blocking antibody NIS793 in combination with gemcitabine/nanoparticle (albumin-bound)-paclitaxel or FOLFIRINOX (folinic acid [FOL], 5-fluorouracil [F], irinotecan [IRI] and oxaliplatin [OX]) in orthotopic pancreatic cancer models. Single-cell RNA sequencing and immunofluorescence were used to evaluate changes in tumor cell state and the tumor microenvironment. Blockade of TGFβ with chemotherapy reduced tumor burden in poorly immunogenic pancreatic cancer, without affecting the metastatic rate of cancer cells. Efficacy of combination therapy was not dependent on CD8 T cells, because response to TGFβ blockade was preserved in CD8-depleted or recombination activating gene 2 (RAG2
−/− ) mice. TGFβ blockade decreased total α-smooth muscle actin–positive fibroblasts but had minimal effect on fibroblast heterogeneity. Bulk RNA sequencing on tumor cells sorted ex vivo revealed that tumor cells treated with TGFβ blockade adopted a classical lineage consistent with enhanced chemosensitivity, and immunofluorescence for cleaved caspase 3 confirmed that TGFβ blockade increased chemotherapy-induced cell death in vivo. TGFβ regulates pancreatic cancer cell plasticity between classical and basal cell states. TGFβ blockade in orthotropic models of pancreatic cancer enhances sensitivity to chemotherapy by promoting a classical malignant cell state. This study provides scientific rationale for evaluation of NIS793 with FOLFIRINOX or gemcitabine/nanoparticle (albumin-bound) paclitaxel chemotherapy backbone in the clinical setting and supports the concept of manipulating cancer cell plasticity to increase the efficacy of combination therapy regimens. Blockade of the cytokine transforming growth factor-β enhances pancreatic tumor cell chemotherapy sensitivity by promoting a basal-like to classical cell state transition. Transforming growth factor-β blockade and combination chemotherapies are currently in clinical trials. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF